Researchers developed a nanodrug delivery system that combines an anti-inflammatory peptide (KPV) with an immunosuppressant drug, designed to target PepT1 transporters in the intestine for treatment of colitis in a mouse model (Evidence level: Animal Model). In DSS-induced colitis models representing both acute and chronic disease, the targeted nanodrug demonstrated improved efficacy compared to free drug components, reducing inflammation and improving disease markers. This work represents a proof-of-concept for peptide-immunosuppressant co-assembly as a targeted delivery strategy, though translation to human clinical use remains to be determined.